CD274 and cancer: Application of monoclonal antibodies targeting immune checkpoints, such as programmed cell death 1 ligand 1 (PD-L1), integrin-associated protein (CD47) and cytotoxic T lymphocyte associated antigen 4 (CTLA-4) has been found to improve the survival rate of patients with several cancer types [152–154].